QGEN Earnings Prediction
The chart below shows how QGEN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, QGEN sees a +1.22% change in stock price 10 days leading up to the earnings, and a +1.11% change 10 days following the report. On the earnings day itself, the stock moves by +0.70%. This data can give you a slight idea of what to expect for the next quarter's release.
QGEN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
521.20M
2.36%
3.85%
Gross Margin
63.60%
3.33%
1.48%
Operating Margin
27.08%
13.50%
5.00%
Net Margin
16.95%
-11.63%
-13.25%
EPS
0.41
-6.82%
-6.82%
No Data Available
QGEN Earnings Analysis
Qiagen NV Corporation (QGEN.N) Earnings Conference Call
Positive
Q4 2024 Net Sales Growth: Net sales for Q4 2024 reached €521 million, growing 3% CER and surpassing the outlook of at least €520 million CER, with core business sales up 4% CER excluding discontinued products.
Earnings Per Share Performance: Adjusted diluted EPS for Q4 2024 was $0.61 CER, exceeding the target of at least $0.60 CER, and for the full year, adjusted EPS reached $2.20 CER, up from the initial target of $2.10 CER.
Strong System Placement Growth: KIAstat Diagnostics achieved 25% CER growth in Q4 2024, with over 616 new system placements throughout the year, exceeding the target of at least 600 placements.
Free Cash Flow Surge: Free cash flow for 2024 was €506 million, reflecting a 63% increase compared to 2023, demonstrating strong cash generation capabilities.
Operating Income Margin Improvement: The adjusted operating income margin improved to 30.6% in Q4 2024, up 2.6 percentage points from the previous year, driven by efficiency gains and a favorable product mix.
Negative
Asia Pacific Sales Decline: Sales in the Asia Pacific Japan region declined by 5% CER in Q4 2024, with China experiencing a low teens CER decline, indicating ongoing market challenges in this key region.
Sales Decline Overview: Sample Technologies sales declined slightly in Q4 2024, contributing to a full-year decline of 3% CER, reflecting lingering headwinds from the pandemic and weaker instrument sales.
SaaS Model Transition Impact: The transition to a SaaS model in the QDI segment adversely impacted results, particularly in the pharmaceutical sector, leading to a modest decline in the discovery portfolio.
Restructuring Charges Overview: Restructuring charges related to the Numodix project amounted to approximately $21 million in Q4 2024, with total expected charges reaching about $400 million, indicating significant financial strain from this corporate action.
External Factors Impacting EPS: External factors are expected to present a headwind of approximately $0.05 CER on adjusted EPS for 2025, primarily due to lower adjusted net interest income and an anticipated increase in the adjusted tax rate.
QGEN FAQs
How does QGEN typically perform around its earnings report dates?
Is Qiagen NV (QGEN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
QGEN Earning Call Sentiment
Qiagen N.V. (NYSE:QGEN) Q4 2024 Earnings Call Transcript
QGEN.N
-1.37%Positive
The earnings call summary presents a positive outlook with strong financial performance, including record revenue and EPS exceeding targets. Product development is solid with FDA clearances, and strategic collaborations enhance market strategy. Shareholder returns are substantial, and financial health is robust with improved margins and cash flow. The Q&A section shows cautious optimism despite competitive pressures and economic factors, but management's guidance and commitment to operational profitability and shareholder returns support a positive sentiment. The absence of a market cap suggests a moderate reaction, likely resulting in a positive stock price movement of 2% to 8%.
